Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Travis Slaba

Physician Assistant, Medical Harrisburg, SD Physician Assistant

NPI 1295732709 CMS profile 11021207

220 S Cliff Ave Ste 120, Harrisburg, SD 57032

Open in the dashboard

General payments

$2,760

166 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Travis Slaba of Harrisburg, SD is reported in the CMS Open Payments database as having received $2,760 across 166 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $806 55
2024 General $1,180 69
2023 General $252 14
2022 General $320 21
2021 General $202 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Travis Slaba
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Travis Slaba were reported at $806. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Travis Slaba Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $202 $156 $41–$563 $132
2022 $320 $185 $55–$649 $149
2023 $252 $199 $58–$717 $160
2024 $1,180 $206 $62–$740 $164
2025 $806 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $488 44 payments
  2. Phathom Pharmaceuticals, Inc. $300 14 payments
  3. Lilly USA, LLC $286 18 payments
  4. Dexcom, Inc. $275 25 payments
  5. Novo Nordisk Inc $230 7 payments
  6. AstraZeneca Pharmaceuticals LP $162 5 payments
  7. Pfizer Inc. $136 8 payments
  8. Axsome Therapeutics, Inc. $117 5 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $91 5 payments
  10. Amgen Inc. $80 5 payments
  11. Other $595 30 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,746 165 payments
  2. Education $14 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $276 11 payments
  2. Dexcom G6 Transmitter $225 21 payments
  3. VOQUEZNA Gastroenterology $172 5 payments
  4. MOUNJARO $150 9 payments
  5. JARDIANCE $137 9 payments
  6. Ozempic $131 2 payments
  7. VOQUEZNA Gastroenterology $129 9 payments
  8. AIRSUPRA $125 3 payments
  9. QULIPTA $120 8 payments
  10. VRAYLAR $118 17 payments
  11. Other $1,993 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 115 drugs

Part D claims

5,147

Median for Physician Assistant: 241

Drug cost

$614,360

Median for Physician Assistant: $4,110

Branded share of claims

24.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 58 $66,100
Mounjaro Tirzepatide Brand 57 $63,186
Ozempic Semaglutide Brand 45 $53,589
Eliquis Apixaban Brand 54 $49,856
Jardiance Empagliflozin Brand 52 $45,689
Synjardy Xr Empagliflozin/Metformin Hcl Brand 48 $43,463
Tresiba Flextouch U-200 Insulin Degludec Brand 28 $41,087
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 50 $33,749
Xarelto Rivaroxaban Brand 29 $31,777
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 14 $20,407

The 10 drugs with the highest cost, of 115 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$53,067

Medicare's payments for the services billed

Medicare patients

273

Average age 73

Services billed

1,234

142 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Diabetes 41%
Arthritis 41%
Chronic kidney disease 28%
Ischemic heart disease 27%
Depression 25%
Osteoporosis 21%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $253
$253 — —
JARDIANCE
  • Lilly USA, LLC $116
  • Boehringer Ingelheim Pharmaceuticals, Inc. $26
$142 52 —
VRAYLAR
  • AbbVie, Inc. $118
$118 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $65
$65 — —
MOUNJARO
  • Lilly USA, LLC $60
$60 57 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record